CLINICAL ROLE -
Chronic Lymphocytic Leukemia: Considerations for Pharmacists
Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.
CAR T for Chronic Lymphocytic Leukemia
Experts discuss the potential future use of CAR T-cell therapy and bispecific therapeutics for chronic lymphocytic leukemia based on data presented at ASH 2021.
Noncovalent Binding BTK Inhibitors for Chronic Lymphocytic Leukemia
Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.
Treatment Selection Strategies for Chronic Lymphocytic Leukemia
Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.
Tumor Lysis and Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.
Chronic Lymphocytic Leukemia: Considerations for Anti-CD20 Monoclonal Antibodies
Anthony Perissinotti, PharmD, BCOP, explains potential scenarios requiring anti-CD20 monoclonal antibodies as a therapy for chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia: The MURANO Study
Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.
Venetoclax-Based Therapies for Chronic Lymphocytic Leukemia
A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.
ASH 2021: A New Formulation for Acalabrutinib
Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.
Second-Generation BTK Inhibitors for Chronic Lymphocytic Leukemia
Kirollos Hanna, PharmD, BCPS, BCOP, discusses clinical trial data for second-generation BTK inhibitors for chronic lymphocytic leukemia.
Treatment Options in Chronic Lymphocytic Leukemia
Anthony Perissinotti, PharmD, BCOP, provides an overview of the available treatment options in chronic lymphocytic leukemia, highlighting the role of first-generation BTK inhibitors.
2 Commerce Drive Cranbury, NJ 08512